Clinical Trials Logo
  1. Home
  2. Vaccines
  3. NCT05401305

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b

Vaccines Clinical Trial

Official title:
Simple Blind, Placebo Controlled, Randomized Safety and Reactogenicity Trial of "Baby-Hib [Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b], Lyophilizate for Preparation of Intramuscular Injection Solution, 0.5 mL/Dose", FSUE SPbSRIVS FMBA of Russia, in Volunteers Aged 18-50

Clinical Trial Summary

Trial purpose is to evaluate the safety, tolerability and reactogenicity of the Vaccine for the prevention of infections caused by Haemophilus Influenzae Type b in volunteers aged 18-50.

Clinical Trial Description

The trial includes 2 stages (Stage I and Stage II). The aim of the Stage I is to assess the tolerability, reactogenicity and safety of the Hib vaccine in the first 10 volunteers during the first 7 days after vaccination. The aim of the Stage I is to assess the tolerability, reactogenicity and safety of the Hib vaccine during 28 days after vaccination and also to conduct a comparative assessment of the safety and reactogenicity of the Hib vaccine and placebo during 28 days after vaccination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05401305
Study type Interventional
Source St. Petersburg Research Institute of Vaccines and Sera
Contact
Status Completed
Phase Phase 1
Start date January 14, 2020
Completion date June 17, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT01461980 - A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age Phase 2
Completed NCT01461993 - A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17 Phase 2
Not yet recruiting NCT05993325 - Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 3
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Active, not recruiting NCT05284097 - Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Phase 2
Recruiting NCT06259487 - Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis. N/A
Active, not recruiting NCT05576623 - Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine Phase 1/Phase 2
Completed NCT03294551 - HPV Centralized R/R RCT #2 - New York State N/A
Not yet recruiting NCT06437834 - Increasing Men's Engagement in Preventive Healthcare Through an Enhanced Cocoon Vaccination Strategy N/A
Completed NCT03666026 - Patient Portal - Flu Reminder Recall N/A
Recruiting NCT05586178 - Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake N/A
Recruiting NCT05586165 - Effects of Prompt to Bundle COVID-19 Booster and Flu Shot N/A
Recruiting NCT05586204 - Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up N/A
Completed NCT03294473 - Centralized Reminder Recall - Flu RCT2 N/A
Completed NCT05593042 - Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile Phase 2
Completed NCT04651790 - Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults Phase 3
Completed NCT01697007 - A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique Phase 2
Completed NCT03548337 - Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India Phase 4
Completed NCT02609035 - Immunization Services Model for Adult Rate Improvement N/A
Active, not recruiting NCT05032976 - Korea Comirnaty Post-marketing Surveillance